Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the m... Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV734, a small molecule G protein biased ligand of the MOR, which has completed phase I studies for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. Trevena, Inc. was incorporated in 2007 and is headquartered in Chesterbrook, Pennsylvania. 詳細を表示
| 期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0.0015 | 0.0015 | 0.0015 | 492 | 0.0015 | CS |
| 4 | 0.0005 | 50 | 0.001 | 0.0111 | 0.001 | 678 | 0.00730763 | CS |
| 12 | -0.0185 | -92.5 | 0.02 | 0.02 | 0.001 | 530 | 0.00907968 | CS |
| 26 | -0.0105 | -87.5 | 0.012 | 0.02 | 0.001 | 778 | 0.01133841 | CS |
| 52 | -1.0585 | -99.858490566 | 1.06 | 1.11 | 0.001 | 1373 | 0.24664121 | CS |
| 156 | -2.1985 | -99.9318181818 | 2.2 | 2.49 | 0.001 | 3173 | 1.41045988 | CS |
| 260 | -2.1985 | -99.9318181818 | 2.2 | 2.49 | 0.001 | 3173 | 1.41045988 | CS |
Truthsocial
17分前
sage007
22分前
eagle8
34分前
brazen22
35分前
jimr1717
36分前
scotty3371
39分前
jimr1717
40分前
price_and_volume
57分前
Lsmith500
1時間前
murrayhill
1時間前
eagle8
2時間前
eagle8
2時間前
tkg
2時間前
tkg
3時間前
fritz603
3時間前
price_and_volume
3時間前
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約
すでにアカウントをお持ちですか? サインイン
アカウントをお持ちでないですか? 登録
登録することで、ADVFN の 利用規約 を読み、理解し、同意したこと、および私が個人投資家であることを確認します。